Australia markets close in 4 hours 31 minutes

Repligen Corporation (RGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
166.52+4.12 (+2.54%)
At close: 04:00PM EDT
166.52 0.00 (0.00%)
After hours: 04:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close162.40
Open162.19
Bid120.00 x 900
Ask199.68 x 800
Day's range161.92 - 166.81
52-week range137.21 - 327.32
Volume181,586
Avg. volume545,604
Market cap9.231B
Beta (5Y monthly)0.98
PE ratio (TTM)64.29
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors

    WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and bioprocessing industry expert. Dr. Konstantinov brings to the director role nearly 30 years of relevant experience, including his current position as Chief Technology Officer at Codiak BioSciences, where he previously served for six years as Executive Vice President, Manufacturing & Process Sciences. D

  • GlobeNewswire

    Repligen Corporation to Present at Upcoming Investor Conferences

    WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at three upcoming investor conferences. Craig-Hallum’s 19th Annual Institutional Investor conference being held June 1. Management will be hosting one-on-one meetings with investors who are registered to attend the conference.William Blair’s 42nd Annual Growth Stock Conference being held in Chica

  • GlobeNewswire

    Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance

    —Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results f